# Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients

> **NCT00410163** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 61 (actual)

## Conditions studied

- Leukaemia, Lymphocytic, Chronic

## Interventions

- **DRUG:** Ofatumumab 500mg
- **DRUG:** Ofatumumab 1000mg
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT00410163
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-01
- **Primary completion:** 2009-03
- **Final completion:** 2013-05
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2014-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00410163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00410163, "Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00410163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*